KIT Ligand anticorps
Aperçu rapide pour KIT Ligand anticorps (ABIN2665356)
Antigène
Voir toutes KIT Ligand (KITLG) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Purification
- The antibody was purified by affinity chromatography.
-
Isotype
- IgG1 kappa
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 0.5 mg/mL
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C
-
Stockage commentaire
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- KIT Ligand (KITLG)
-
Autre désignation
- SCF
-
Sujet
- Stem Cell Factor (SCF) is initially synthesized as membrane-bound forms of 248 or 220 amino acids, depending on the alternative splicing of exon 6. The 248 amino acid form contains a proteolytic cleavage site encoded by exon 6, and it is cleaved from the cell to release an active soluble protein of 165 amino acid residues. Soluble SCF is glycosylated at both N-linked and O-linked sites. MMP-9 plays a physiological role in SCF release from the membrane, and this action plays a significant role in differentiating and mobilizing stem and progenitor cells from the bone marrow. SCF increases the proliferation of myeloid and lymphoid hematopoietic progenitors in bone marrow cultures. SCF/c-kit interaction in mast cells results in mast cell degranulation that induces the release of mediators, such as histamine and inflammatory cytokines and chemokines. Also, activation of c-kit in dendritic cells regulates T helper cell differentiation and allergic asthma. In addition, SCF plays an important role in revascularization of ischemic limbs. Ischemia induces plasma elevation of SCF, thrombopoietin (TPO), erythropoietin (EPO), and GM-CSF albeit at lower levels. SCF and TPO induce the release of CXCL12 from platelets, which increase CXCL12 levels in plasma. This results in an extensive mobilization of CXCR4+VEGFR1+ cells (hemangiocytes) that accelerate revascularization of the ischemic limbs. SCF binds to its receptor c-kit, which belongs to the type III tyrosine kinase family whose members include receptors for M-CSF and PDGF.
-
Pathways
- Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
Antigène
-